Related Experiment Videos
C-reactive protein levels are not associated with increased risk for colorectal cancer in women
Shumin M Zhang1, Julie E Buring, I-Min Lee
1Brigham and Women's Hospital, Harvard Medical School, and Harvard School of Public Health, Boston, Massachusetts.
Annals of Internal Medicine
|March 16, 2005
Summary
Plasma C-reactive protein (CRP) levels do not predict colorectal cancer risk in healthy women. This suggests low-grade inflammation may not be a significant factor in developing this cancer.
Area of Science:
- Oncology
- Inflammation Research
- Preventive Medicine
Background:
- Inflammatory bowel disease is linked to elevated colorectal cancer (CRC) risk.
- Anti-inflammatory drug use may reduce CRC risk, suggesting a role for inflammation.
- C-reactive protein (CRP) is a marker of inflammation, but its link to CRC risk is not well-established.
Purpose of the Study:
- To investigate if plasma CRP levels can predict CRC risk in women.
- To explore the association between inflammation markers and colorectal cancer development.
Main Methods:
- A prospective cohort study involving 27,913 healthy women aged 45+.
- CRP levels were measured at baseline.
- Follow-up for colorectal adenocarcinoma incidence over a maximum of 10.8 years.
Main Results:
- No significant association was found between baseline CRP levels and colorectal cancer risk.
- Hazard ratios for CRC risk were not elevated even at higher CRP levels.
- Subgroup analyses and alternative cutoff points also showed no significant link.
Conclusions:
- Plasma CRP levels do not appear to predict increased risk of developing colorectal cancer in apparently healthy women.
- Low-grade inflammation may not play a significant role in increasing colorectal cancer risk.
- Further research may be needed to address potential residual confounding or undetected baseline cancers.